Special Issue

COVID-19 and Vaccination Strategies in Global Health

Message from the Guest Editor

We have faced challenging times since the beginning of the COVID-19 pandemic. It has affected us all in an unprecedented way, pushing medical authorities, pharmaceutical companies, scientists, patients, and their relatives to find and test solutions which could limit the spread of the Sars-Cov-2 virus or its consequences on our health and on our lives. As we all know, vaccines have played a major role, both in the scientific debate and in the attempt to contain the pandemic. The year 2022, the third year since the start of the pandemic, has provided an opportunity to update what we know, revise what we thought, and envisage what can be done further to manage pandemics such COVID-19 and eventually prevent future ones. I therefore invite you all to contribute to this Special Issue of Vaccines on 'COVID-19 and Vaccination Strategies in Global Health' with original research articles, reports, and reviews. The scope of this Special Issue is purposefully wide, in order to tackle different points of view: immunology, infectiology, epidemiology, public health, primary care, and medical statistics.

Guest Editor

Dr. Davide Barbieri

Department of Neuroscience and Rehabilitation, University of Ferrara, Ferrara, Italy

Deadline for manuscript submissions

closed (31 March 2024)



an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/152381

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines





an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 9.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

